A generic version of Absorica® (isotretinoin capsules) has been made available by Teva Pharmaceuticals.
Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5mm or greater. The generic product is available 6 dosage strengths: 10mg, 20mg, 25mg, 30mg, 35mg, and 40mg.
Due to the potential for significant adverse reactions, the product is only available through a restricted program (iPLEDGE® REMS) and is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.
Teva announces the launch of the first generic version of Absorica® (isotretinoin) capsules, for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older, in the United States. [press release]. Tel Aviv, Israel and Parsipanny, NJ; Teva Pharmaceuticals: April 29, 2021.